=Amicus Therapeutics (FOLD) : positive data in Pompe disease study

Amicus Therapeutics announces additional 'positive' results from a Phase 1/2 clinical study to investigate ATB200/AT2221 in patients with Pompe disease
Consistent with previous results, patients who completed six months of treatment with ATB200/AT2221 showed improvements in six-minute walk test (6MWT) distance and other measures of motor function, stability or increases in forced vital capacity (FVC), and further reductions in biomarkers of muscle damage and disease substrate, with consistent results reported in initial patients who completed nine months of treatment. Co plans to continue a series of collaborative discussions with regulators in the US and EU, and expects to provide an update in the first half of 2018.